Cancer Family
Malignant Peritoneal and Retroperitoneal Neoplasm
CI-CAN-00000248Explore in graph →
163 active trials6 approved drugs2 evidence items
- NCIt
- C156711
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000248Explore in graph →
Clinical trials
631 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (92)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06483997 | Diet, Hepcidin, and Chemotherapy RDI | active not recruiting | — | 100 | George Washington UniversityOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT05036434 | Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma(ACCOMPLISH) | active not recruiting | Phase 2 | 30 | National Cancer Center, KoreaOTHER_GOV | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07335679 | Characterization of the Strasbourg Cohort of Patients With Adrenal Cortex Carcinoma(CCSTR) | recruiting | — | 60 | University Hospital, Strasbourg, FranceOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT05041257 | Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers(PICCOLO) | completed | Phase 2 | 79 | AbbVieINDUSTRY | 7 | Jan 9, 2026 | clinicaltrials |
| NCT02324647 | Structured Evaluation of adRENal Tumors Discovered Incidentally - Prospectively Investigating the Testing Yield(SERENDIPITY) | completed | — | 807 | University Medical Center GroningenOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT03746431 | A Phase 1 Study of [225Ac]-FPI-1434 Injection | terminated | Phase 1 | 78 | Fusion Pharmaceuticals Inc.INDUSTRY | 3 | Jan 7, 2026 | clinicaltrials |
| NCT04204811 | Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy | active not recruiting | N/A | 22 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT00565851 | Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 3 | 1,052 | National Cancer Institute (NCI)NIH | 3 | Dec 30, 2025 | clinicaltrials |
| NCT05483933 | Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers | completed | Phase 1 | 86 | Shattuck Labs, Inc.INDUSTRY | 4 | Dec 23, 2025 | clinicaltrials |
| NCT02364713 | MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer | terminated | Phase 2 | 17 | Mayo ClinicOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT05224934 | Preoperative Ultra-hypofractionated Radiotherapy Followed by Surgery for Retroperitoneal Sarcoma (FUSION-01)(FUSION-01) | recruiting | N/A | 50 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT07269574 | Impact of Dietary Patterns on Prognosis of Ovarian Cancer Patients During PARPi Maintenance | not yet recruiting | — | 600 | Tongji HospitalOTHER | 0 | Dec 8, 2025 | clinicaltrials |
| NCT06870539 | Feasibility of Saliva and Remote Monitoring of Active Cytomegalovirus (CMV) Infection and Symptoms During Ovarian Cancer Treatment | completed | — | 49 | Mayo ClinicOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT04224948 | The PET- Retroperitoneal Sarcoma Study(PET-RPS) | completed | N/A | 18 | University Health Network, TorontoOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT06333314 | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI(Pan-MSI-ACSE) | recruiting | Phase 2 | 120 | UNICANCEROTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT05236686 | Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer | recruiting | N/A | 94 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Nov 19, 2025 | clinicaltrials |
| NCT02111941 | Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Early Phase 1 | 19 | Mayo ClinicOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT03325634 | Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Primary Ovarian or Uterine Cancer | completed | Phase 1 | 15 | University of Colorado, DenverOTHER | 1 | Oct 23, 2025 | clinicaltrials |
| NCT06084416 | A Study of Sovilnesib in Subjects With Ovarian Cancer | active not recruiting | Phase 1 | 120 | Volastra Therapeutics, Inc.INDUSTRY | 1 | Oct 20, 2025 | clinicaltrials |
| NCT06812052 | Short Course Radiation Treatment for Patients With Primary or Locally Recurrent Retroperitoneal Sarcoma Prior to Surgery | recruiting | Phase 1 | 6 | Brigham and Women's HospitalOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT03776812 | Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 178 | Corcept TherapeuticsINDUSTRY | 5 | Oct 7, 2025 | clinicaltrials |
| NCT07085572 | Cemiplimab as Maintenance Treatment for Advanced Adrenocortical Cancer(INTERVAL) | recruiting | Phase 2 | 31 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT05200364 | A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer | terminated | Phase 1 | 58 | Sutro Biopharma, Inc.INDUSTRY | 1 | Sep 22, 2025 | clinicaltrials |
| NCT03029403 | Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer | active not recruiting | Phase 2 | 47 | University Health Network, TorontoOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT06451263 | Nudge to Gynecologic Oncology | active not recruiting | N/A | 20 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT05009082 | Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer | recruiting | Phase 3 | 970 | AGO Study GroupOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT07141147 | A Prospective, Randomized, Multicenter Clinical Study Comparing Adjuvant Radiotherapy Versus Observation in High-risk Localized Adrenocortical Carcinoma After Surgery. | not yet recruiting | N/A | 58 | Sun Yat-sen UniversityOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT05449366 | Intraperitoneal Paclitaxel for Patients With Primary Malignant Peritoneal Mesothelioma(INTERACT MESO) | completed | Phase 1 / Phase 2 | 7 | Erasmus Medical CenterOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT02498600 | Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 100 | National Cancer Institute (NCI)NIH | 1 | Aug 29, 2025 | clinicaltrials |
| NCT01767675 | Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 99 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT03748186 | Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers | completed | Phase 1 | 136 | Sutro Biopharma, Inc.INDUSTRY | 2 | Aug 20, 2025 | clinicaltrials |
| NCT05708924 | MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | terminated | Phase 1 | 1 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT06634706 | SCINTIX [BgRT} Using RMRS in Solid and Soft Tissue Tumors | not yet recruiting | N/A | 96 | RefleXion MedicalINDUSTRY | 0 | Aug 13, 2025 | clinicaltrials |
| NCT04611126 | T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer | terminated | Phase 1 / Phase 2 | 6 | Inge Marie SvaneOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT05406674 | Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian Cancer(CisCon) | active not recruiting | Phase 2 | 40 | The Netherlands Cancer InstituteOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT07022535 | Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer(PRESELECT-0) | recruiting | Phase 2 | 18 | The University of Hong KongOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT07023484 | Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer(Preselect-1) | recruiting | Phase 2 | 126 | The University of Hong KongOTHER | 2 | Jul 2, 2025 | clinicaltrials |
| NCT05274451 | A Study to Investigate LYL797 in Adults With Solid Tumors | terminated | Phase 1 | 57 | Lyell Immunopharma, Inc.INDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
| NCT05891197 | A Biomarker Screening Protocol for Participants With Solid Tumors(START) | terminated | — | 10 | Lyell Immunopharma, Inc.INDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
| NCT06602063 | Surgery for Relapsed Ovarian Cancer in Precision | not yet recruiting | Phase 1 / Phase 2 | 33 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Jun 27, 2025 | clinicaltrials |
| NCT05634577 | A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma | terminated | Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 19, 2025 | clinicaltrials |
| NCT05788484 | A Study of CDX-585 in Patients With Advanced Malignancies | completed | Phase 1 | 20 | Celldex TherapeuticsINDUSTRY | 1 | Jun 15, 2025 | clinicaltrials |
| NCT03783949 | European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer(EUDARIO) | completed | Phase 2 | 122 | Universitaire Ziekenhuizen KU LeuvenOTHER | 5 | Jun 11, 2025 | clinicaltrials |
| NCT04019288 | AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | terminated | Phase 1 / Phase 2 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT06087289 | A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer(KANDOVA) | completed | Phase 1 / Phase 2 | 18 | Novakand Pharma ABINDUSTRY | 3 | Jun 8, 2025 | clinicaltrials |
| NCT02419495 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | terminated | Phase 1 | 221 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT06393751 | Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Jun 3, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 29, 2026source: clinicaltrials